Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENGA: 68Ga-tilmanocept PET/CT for SLN mapping in endometrial cancer
NCT05446324Phase 3Unknown
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gallium Ga 68 tilmanocept in endometrial cancer (EC). Status: unknown.
02
Drugs
gallium Ga 68 tilmanocept
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05446324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446324.